tbuckley/cabot-search huggingface dataset:
Long-term data for endoscopic ultrasound (EUS) and percutanous (PTA) guided intratumoral TNFerade gene delivery combined with chemoradiation in the treatment of locally advanced pancreatic cancer (LAPC)
Authors: J Farrell, N Senzer, N Hanna, T Chung, J Nemunaitis, A Rosemurgy, M Javle, T Reid, M Posner, K Chang, J Macko, JR Hecht
Journal: Endoscopy (2006)

Background: TNFerade is a replication-deficient adenoviral vector containing the TNF-α gene regulated by a chemoradiation-inducible promoter, Egr-1. This large dose-selection phase II study compared the safety and activity of EUS or PTA delivery of TNFerade with chemoradiation in patients with LAPC. Methods: Dose-escalating design was used. 5-week treatment consisted of weekly injections of 4×109, 4×1010, 4×1011 or 1×1012 pu TNFerade, continuous infusion 5-FU and radiation. TNFerade was delivered by PTA or EUS guided intratumoral injections. Endpoints: Safety, tumor response and progression, CA 19–9 and survival. EUS and PTA groups were compared. Results: 50 pts completed this study (n=27 (EUS), n=23 (PTA)). Dose-limiting toxcities (DLTs) occurred in a PTA patient and 3 EUS patients, setting the maximally tolerated dose (MTD) at 4×1011 pu. Serum TNF-αmax was 129 pg/ml. Compared with the first 2 cohorts (n=30), the MTD (n=11) was associated with greater locoregional control of treated tumors, longer progression-free survival, a greater proportion of patients with stable or decreasing CA 19–9, a greater percentage (45%) of patients resected, and improved median survival (6.6, 8.8, 11.2, and 10.9 months, in the 4×109, 4×1010, 4×1011 or 1×1012 pu cohorts, respectively). At the MTD, 4/5 patients reassessed as surgically resectable achieved pathologically negative margins, and 3 survived >24 months. Disease control and survival were for both the PTA and EUS group. Conclusions: EUS or PTA guided intratumoral delivery of TNFerade, combined with chemoradiation shows promise in the treatment of LAPC. The dose of 4×1011 pu TNFerade is generally well tolerated with encouraging indications of activity, and will be tested in the randomized phase of this study. EUS and PTA are similarly effective for delivery of TNFerade and did not interfere with subsequent surgical resection.
APPROPRIATENESS OF COLONOSCOPY INDICATIONS ACCORDING TO THE NEW EPAGE II CRITERIA IN A MOROCCAN UNIVERSITY HOSPITAL
Authors: S Jamal, Y Touibi, S Berrag, F Bouhamou, S Morabit, F Miyabe, F Nejjari, M Tamzaourte, F Rouibaa, A Aourarh
Journal: Endoscopy (2018)

The demand for gastrointestinal endoscopy is increasing, resulting in an important rise in overall costs and waiting lists for endoscopic procedures. Therefore, adherence to appropriate indications for these procedures is essential for the rational use of the criteria for the appropriateness for colonoscopy EPAGE (European Panel on the Appropriateness of Gastrointestinal Endoscopy) have been elaborated by a European expert panel, published in 1999 and have been updated in April 2008. Objectives:
THE INCIDENCE AND CHARACTERISTICS OF INTERVAL COLORECTAL CANCER IN CSONGRAD COUNTY IN HUNGARY
Authors: R Bor, A Fábián, M Rutka, B Vasas, F Szántó, A Bálint, K Farkas, Á Milassin, T Molnár, K Szántó, Z Szepes
Journal: Endoscopy (2018)

The incidence of interval colorectal cancer (CRC) is one of the most important quality indicators of national CRC screening programs. Aim of our retrospective study was to evaluate the incidence, clinical characteristics and risk factors of interval CRC.
EUS GUIDED RECANALIZATION OF COMPLETE OESOPHAGEAL STRICTURE
Authors: C Mangas, J Martínez, L Compañy, FA Ruíz, JA Casellas, J Ramón Aparicio
Journal: Endoscopy (2018)

Endoscopic treatment of complete oesophageal strictures is sometimes difficult. However, if the distance between the proximal and the distal end of the stricture is short, it's possible to recanalize the esophagus by direct wire-guided puncture under transillumination. If it's not possible, endoscopy ultrasound (EUS) might be a useful tool. The aim was to use EUS to localize the distal end of a stenosis located in the esophagus.
ASSOCIATED FACTORS WITH OVERLOOKED NEOPLASIA AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION
Authors: CW Choi, DH Kang, HW Kim, SJ Kim, BJ Kwon
Journal: Endoscopy (2018)

Since endoscopic submucosal dissection (ESD) has been accepted treatment choice for early gastric cancer (EGC) without risk of lymph node metastasis, missed gastric epithelial neoplasia at the time of ESD is not infrequent in the clinical practice. Knowledge about the risk factors associated with overlooked gastric epithelial neoplasia is important to provide optimal treatment.
Abstract P156: Comorbidity Profile Preceding Dementia Diagnosis: Findings From the Atherosclerosis Risk in Communities (ARIC) Study Cohort
Authors: Anna Kucharska-Newton, David Knopman, Priya Palta, Gerardo Heiss
Journal: Circulation (2018)

Background: Most patients receive a diagnosis of dementia late in the course of the disease. In an effort to learn more about the potential for earlier detection, we examined comorbidity burden preceding a diagnosis of dementia in a cohort of older adults. Methods: Cognitive status of ARIC Study cohort participants (n=6,538) was adjudicated at Visit 5 (2011-2013) by a classification committee of physicians and neuropsychologists using a battery of neurocognitive tests, functional assessments, and neurologic exam. Additionally, cognitive status of participants who did not attend the Visit 5 examination, but were alive at the time of the visit (n= 2,289) was ascertained through a Telephone Interview for Cognitive Status-Modified (TICS) or Clinical Dementia Rating (CDR) informant interview. We examined the presence of dementia diagnostic codes in claims for inpatient and outpatient services occurring during the years 1991-2013 and preceding dementia diagnoses among all ARIC cohort participants with a dementia classification. In a sample of study participants who were enrolled in continuous fee-for-service (FFS) Medicare for at least 5 years prior to dementia ascertainment, we examined the comorbidity profile preceding the date of dementia ascertainment using ICD9 diagnostic codes obtained from inpatient records and claims for outpatient office visits. Results: Of the 7,283 ARIC participants enrolled in FFS Medicare at the time of ARIC dementia ascertainment (39.6% men, 26.4% black, mean age 76.7 years (SD 5.4)), 901 (12.4%) were classified as having dementia. Only 41.3% of those classified with dementia and 2.6% of those classified as cognitively intact had dementia diagnostic codes in any position in claims for inpatient or outpatient care preceding the ascertainment of cognitive status. In analyses limited to participants with 5 years of continuous FFS Medicare enrollment prior to the cognitive status ascertainment, we observed a consistently greater frequency of hospitalizations among study participants with a subsequent dementia classification, as compared to those with no cognitive impairment (1.62 (SD 0.08) vs. 1.10 (SD 0.05) hospitalizations per participant in the year preceding dementia diagnosis, respectively). No difference in the frequency of outpatient visits was observed. In addition to a greater frequency of diagnostic codes for cerebrovascular disease and cerebral degeneration, those with a positive dementia classification had a greater prior frequency of ICD9 codes for depression, heart failure, acute renal failure, and fluid and electrolyte disorders, as compared to those with no cognitive impairment. Conclusion: Dementia patients may have distinct comorbidity profiles in the years preceding a diagnosis. A greater understanding of these profiles is important for characterizing patient factors that may enable early detection and management.
SAFETY AND EFFICACY OF EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY FOR DIFFICULT-TO-RETRIEVE COMMON BILE DUCT STONES: A TEN YEAR EXPERIENCE
Authors: M Manzoor ul Haque, N Hassan Luck, A Ali Tasneem
Journal: Endoscopy (2018)

Extracorporeal shock wave lithotripsy (ESWL) for common bile duct (CBD) stones has been used in the past but experience is limited. We, herein, report our experience regarding ESWL in the management of difficult to retrieve biliary stones.
EUS and Magnetic Resonance Image (MRI) in the staging of rectal cancer. A prospective and comparative study
Authors: A Ginès, G Fernández-Esparrach, JR Ayuso-Colella, O Sendino, C Ayuso-Colella, M Pagés, M Cuatrecasas, L Jáuregui, M Pellisé, J Maurel, JM Bordas, J Llach, A Castells
Journal: Endoscopy (2011)

Background: Accurate locorregional staging is crucial in rectal cancer for deciding patients' management, since the administration of neoadjuvant therapy depends on it. EUS and MR are used in the pretherapeutic work-up of rectal cancer. However, both techniques have not been prospectively compared in a large series of patients.
Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model
Authors: Yuri Kosinsky, Simon J. Dovedi, Kirill Peskov, Veronika Voronova, Lulu Chu, Helen Tomkinson, Nidal Al-Huniti, Donald R. Stanski, Gabriel Helmlinger
Journal: Journal for ImmunoTherapy of Cancer (2018)

<h3>Background</h3> Numerous oncology combination therapies involving modulators of the cancer immune cycle are being developed, yet quantitative simulation models predictive of outcome are lacking. We here present a model-based analysis of tumor size dynamics and immune markers, which integrates experimental data from multiple studies and provides a validated simulation framework predictive of biomarkers and anti-tumor response rates, for untested dosing sequences and schedules of combined radiation (RT) and anti PD-(L)1 therapies. <h3>Methods</h3> A quantitative systems pharmacology model, which includes key elements of the cancer immunity cycle and the tumor microenvironment, tumor growth, as well as dose-exposure-target modulation features, was developed to reproduce experimental data of CT26 tumor size dynamics upon administration of RT and/or a pharmacological IO treatment such as an anti-PD-L1 agent. Variability in individual tumor size dynamics was taken into account using a mixed-effects model at the level of tumor-infiltrating T cell influx. <h3>Results</h3> The model allowed for a detailed quantitative understanding of the synergistic kinetic effects underlying immune cell interactions as linked to tumor size modulation, under these treatments. The model showed that the ability of T cells to infiltrate tumor tissue is a primary determinant of variability in individual tumor size dynamics and tumor response. The model was further used as an in silico evaluation tool to quantitatively predict, prospectively, untested treatment combination schedules and sequences. We demonstrate that anti-PD-L1 administration prior to, or concurrently with RT reveal further synergistic effects, which, according to the model, may materialize due to more favorable dynamics between RT-induced immuno-modulation and reduced immuno-suppression of T cells through anti-PD-L1. <h3>Conclusions</h3> This study provides quantitative mechanistic explanations of the links between RT and anti-tumor immune responses, and describes how optimized combinations and schedules of immunomodulation and radiation may tip the immune balance in favor of the host, sufficiently to lead to tumor shrinkage or rejection.
IMPACT OF TRAINEE INVOLVEMENT ON CANNULATION TECHNIQUE AT ERCP: INTERIM ANALYSIS FROM A MULTICENTER OBSERVATIONAL STUDY
Authors: T Voiosu, A Ladic, A Voiosu, A Benguş, A Gheorghe, B Mateescu, N Rustemovic
Journal: Endoscopy (2018)

Despite advances in recent years we currently lack a formal algorithm for training endoscopists in ERCP and data regarding technical success and outcomes of procedures involving trainees is very limited. We aimed to analyze the impact of trainee involvement on the cannulation technique of the common bile duct.
EUS-GUIDED RADIOFREQUENCY ABLATION OF SMALL PANCREATIC ADENOCARCINOMA: A NEW THERAPEUTIC OPTION FOR PATIENTS UNFIT FOR SURGERY
Authors: I Tarantino, D Ligresti, F Cipolletta, M Amata, L Barresi, A Granata, M Traina
Journal: Endoscopy (2018)

Radiofrequency ablation (RFA) is a well-established therapeutic option for ablation of neoplastic tissue. EUS-guided RFA is a mini-invasive approach that offers a high quality real-time imaging guidance during selective ablation of pancreatic lesions. It has been demonstrated feasible and safe in patients with unresectable pancreatic cancer. We present a case of a EUS-guided RFA of a resectable small pancreatic adenocarcinoma in a patient unfit for surgery.
A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone
Authors: Mrinal M. Patnaik, None Rangit Vallapureddy, Terra L. Lasho, Katherine P. Hoversten, Christy M. Finke, Rhett P. Ketterling, Curtis A. Hanson, Naseema Gangat, Ayalew Tefferi, Animesh Pardanani
Journal: Leukemia (2018)
Overdose Deaths Involving Opioids, Cocaine, and Psychostimulants — United States, 2015–2016
Authors: Puja Seth, Lawrence Scholl, Rose A. Rudd, Sarah Bacon
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

cdc-drug-surveillancereport.pdf.§ Natural opioids include morphine and codeine, and semisynthetic opioids include drugs such as oxycodone, hydrocodone, hydromorphone, and oxymorphone.Methadone is a synthetic opioid.Synthetic opioids, other than methadone, include drugs such as tramadol and fentanyl.Heroin is an illicit opioid synthesized from morphine that can be a white or brown powder, or a black sticky substance.¶ https://www.cdc.gov/nchs/products/databriefs/db294.htm.treatment, and more collaboration between public health and public safety agencies.Drug overdose deaths were identified in the National Vital Statistics System multiple cause-of-death mortality files,** using the International Classification of Diseases, Tenth Revision (ICD-10), based on ICD-10 underlying cause-of-death codes X40-44 (unintentional), X60-64 (suicide), X85 (homicide), or Y10-Y14 (undetermined intent).Among deaths with drug overdose as the underlying cause, the type of drug or drug category is indicated by the following ICD-10 multiple cause-of-death codes: opioids (T40.0,T40.1, T40.2, T40.3,
A single-cell hematopoietic landscape resolves 8 lineage trajectories and defects in Kit mutant mice
Authors: Joakim S. Dahlin, Fiona K. Hamey, Blanca Pijuan-Sala, Mairi Shepherd, Winnie W. Y. Lau, Sonia Nestorowa, Caleb Weinreb, Samuel Wolock, Rebecca Hannah, Evangelia Diamanti, David G. Kent, Berthold Göttgens, Nicola K. Wilson
Journal: Blood (2018)
MANAGEMENT OF ESOPHAGEAL ANASTOMOTIC LEAKS WITH SELF-EXPANDING METAL STENTS AFTER TOTAL ESOPHAGECTOMY OR GASTRECTOMY
Authors: V Anapaz, D Aparício, R Carvalho, A Oliveira, L Lourenço, L Santos, D Horta, N Pignatelli, A Gomes, V Nunes, J Reis
Journal: Endoscopy (2018)

Esophageal, gastric and esophageal-jejunal anastomotic leaks (EEAL) after oncologic curative surgery are associated with considerable morbidity and mortality. The aim of the present study was to report our experience and assess the efficacy of self-expanding metal stents in the treatment of EEAL.
Incomplete Pancreas Divisum: Is It Merely a Normal Anatomic Variant without Clinical Implications?
Authors: M.-H. Kim, S. S. Lee, C. D. Kim, S. K. Lee, H.-J. Kim, H.-J. Park, Y. H. Joo, D. I. Kim, K.-S. Yoo, D. W. Seo, Y. I. Min
Journal: Endoscopy (2001)

Background and Study Aims: Incomplete pancreas divisum (PD) has been generally regarded as merely a normal anatomic variant, without clinical implications. This study compares the prevalence, symptom occurrence rate, clinical presentation, and outcomes of endoscopic treatment in patients with incomplete PD and those with complete PD.
POOR AGREEMENT BETWEEN BIOPSIES AND ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) SPECIMENS ON GASTRIC LESIONS: A SPANISH MULTICENTRE COHORT STUDY
Authors: JC Marín-Gabriel, F Ramos-Zabala, F Múgica-Aguinaga, E Albéniz Arbizu, J de la Peña-García, A Sánchez-Yagüe, C Dolz-Abadía, G Fernández-Esparrach, A Álvarez-Delgado, Á Terán-Lantarón, H Cortés-Pérez, AJ del Pozo-García, J Díaz-Tasende
Journal: Endoscopy (2018)

To assess the agreement between the biopsy specimens obtained during the diagnostic upper endoscopy and the ESD specimen for gastric lesions.
Abstract 15076: Altered Trafficking of Junctional Proteins Mediated by SAP97 in Arrhythmogenic Cardiomyopathy
Authors: Angeliki Asimaki, Sudhir Kapoor, Eva Plovie, Zhen Zhen Liu, Calum A MacRae, Andre G Kleber, Jeffrey E Saffitz
Journal: Circulation (2013)

We have shown that expression of 2057del2 plakoglobin, known to cause arrhythmogenic cardiomyopathy (AC) in patients, leads to ~75% reductions in INa and IK1 current densities in zebrafish ventricular myocytes. Trafficking of Nav1.5 (INa) and Kir2.1 (IK1) to the cell surface is coordinately regulated by the MAGUK protein SAP97. To determine if altered SAP97 distribution plays a role in AC, we immunostained neonatal rat ventricular myocytes expressing 2057del2 plakoglobin and observed dramatic loss of both SAP97 and Nav1.5 immunoreactive signals. However, immunoblotting showed no apparent change in total cellular content of these proteins, thus strongly suggesting a trafficking defect. The normal pattern of SAP97 and Nav1.5 immunostaining was restored completely by incubating cells in SB216763, a small molecule shown previously to rescue the heart failure phenotype, reduce mortality and restore normal cell electrophysiology in the 2057del2 plakoglobin model of AC in fish. Knock-down of SAP97 expression using shRNA in normal rat myocytes prevented junctional localization of Nav1.5 as expected, but also reduced cell surface localization of plakoglobin (but not other desmosomal proteins including desmoplakin and plakophilin-2). These observations in fish and rat models suggest that altered forward trafficking of Nav1.5, mediated by SAP97, is an important disease mechanism in AC. The unexpected finding that forward trafficking of plakoglobin is also regulated by SAP97 suggests a central role for SAP97 in the normal localization of critical cell-cell junction proteins and implicates abnormal SAP97 distribution in both electrophysiological abnormalities and altered Wnt signaling dependent on abnormal localization of plakoglobin in AC. To determine if abnormal SAP97 distribution occurs in patients, we immunostained myocardium from 11 patients with AC including 8 with desmosomal gene mutations. SAP97 signal was markedly reduced in all AC samples but not in myocardium from patients with end-stage ischemic, dilated or hypertrophic cardiomyopathies (n=5 for each). Taken together, these observations show that altered SAP97-mediated trafficking is critical in the disease pathway in AC, and identify SAP97 as a potential new biomarker in AC.
CONTEMPORARY STRETTA THERAPY FOR GASTROESOPHAGEAL REFLUX DISEASE IN THE MODERN DAY ERROR OF THE PPI CONCERNS, FRIEND OR FOE?
Authors: M Rasool Aljabiri, O Rathore, K Shamsheer, L Mediodia, A Pradeep, A Santos, E Daulat, C Villaranda, D Rabon, L Ipo, M Concepcion, J Villanueva, T Lazaro, A Belizario, G George, S Devassy, A Eslim, D Noble, A Suralal, R Krishnan, A Kahlenberg, H Gattner, K McCombe, K Mordani, M Abdulla, M Bertin, M Aboukofa, S Sherllalah, Z Nesnas, L Atteeq, C Aznar
Journal: Endoscopy (2018)

Gastroesophageal reflux disease (GORD) is one of the leading gastrointestinal disorders, Patients with GORD often seek alternative therapy for inadequate symptom control, with over 40% not responding to medical treatment. Current treatments include lifestyle modifications, pharmacological therapies, surgical and STRETTA therapy that is a minimally invasive procedure that significantly reduces GORD symptoms, allowing the majority of patients to eliminate or decrease use of PPIs.
Trans-intra-arterial gemcitabine versus continuation of IV gemcitabine and nab-paclitaxel following radiotherapy for locally advanced pancreatic cancer (TIGeR-PaC).
Authors: Michael J. Pishvaian, Karyn A. Goodman, Emmanuel E. Zervos, Peter Muscarella, Alexander Y. Kim, Mark Bloomston, Charles W. Nutting, Ken Lee Meredith, Harish Lavu, Jennifer W. Chuy, Justin Lee, Marc Ryan Matrana, Clifford Lavarias, Scott Gellert, Ramtin Agah
Journal: Journal of Clinical Oncology (2018)

TPS529 Background: Treatment of locally advanced pancreatic cancer (LAPC) remains a challenge, and novel therapy options for local treatment of disease beyond systemic therapy are needed. Recently published data of intra-arterial delivery of gemcitabine (IAG) for local disease control has shown this approach to be safe (J. Pancreatic Cancer 3(1) 58:65). Furthermore, in patients who have received prior radiation for LAPC, there seems to be an effect on the local microvasculature that enhances the clinical efficacy of IAG. TIGeR-PaC is a randomized Phase 3 trial designed to test if the combination of induction systemic chemotherapy plus radiation followed by IAG is superior to systemic chemotherapy plus radiation alone (NCT03257033). Methods: All subjects with biopsy proven, and imaging-confirmed LAPC (by the NCCN guidelines) will receive induction therapy with IV gemcitabine plus nab-paclitaxel, for approximately four months, during which time a course of radiation therapy will also be incorporated. Subjects without evidence of disease progression will then be randomized to receive either IAG (test group); or continue only IV gemcitabine plus nab-paclitaxel (control group). Subjects will receive the randomized treatments for up to 16 weeks or until progression. Non-progressing patients from both groups will then receive, at the discretion of the investigator, either a continuation of IV gemcitabine and nab-paclitaxel, or oral capecitabine until disease progression. The primary endpoint is progression free survival; secondary endpoints will include overall survival, neutropenia, quality of life, and neuropathy assessed over 2 years. Based on an assumed superiority of IAG therapy, which will lead to an increased PFS from 6 months (control group) up to 12 months (IAG group), with an alpha-error of 0.05 and a 90% power, 132 patients will be randomized; assuming a 30% dropout during the induction phase prior to randomization, 200 patients will be recruited. TIGeR-PaC will test the hypothesis that IAG local therapy, after induction systemic chemotherapy plus radiation in patients with LAPC is superior to systemic therapy plus radiation alone. Clinical trial information: NCT03257033.
EVALUATION OF AN INNOVATIVE 3D IMAGE GUIDED COLONOSCOPE SYSTEM USING FIBER BRAG GRATING ARRAY – 3D COLONOSCOPE SHAPE IMAGING BASED ON FIBER BRAG GRATING ARRAY
Authors: W Kim, B Keum, SJ Choi, G Min, JM Lee, SH Kim, JM Lee, HS Choi, ES Kim, YT Jeen, HJ Chun, HS Lee, CD Kim, S Yang, MS Jang, J Kim
Journal: Endoscopy (2018)

Colonoscopy is a challenging procedure due to unpredictable looping during insertion. If the endoscopist is able to see the colonoscope on the image display, fewer attempts are needed to straighten the shaft of the scope. A prototype Fiber Brag Grating (FBG) scope guided endoscopy provides a facility for continuous viewing on a monitor of the position of the colonoscope during examination. The aim of this study was to evaluate the accuracy and feasibility of the innovative 3D Colonoscope using FBG.
RISK FACTORS FOR COMPLICATIONS RELATED TO THERAPEUTIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP): AN ANALYSIS OF 505 CASES
Authors: K Agar, M Medhioub, S Jardak, L Hamzaoui, A Khsiba, M Msaddek Azouz
Journal: Endoscopy (2018)

Endoscopic retrograde cholangiopancreatography (ERCP) is an effective therapy for pancreatobiliary disease with less morbidity compared to surgery.